The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication
Open accessAbstract
Background: In order to increase eradication rates, vonoprazan, a novel potassium‐competitive acid blocker, has been used in Helicobacter pylori eradication therapy. Aim: To summarise the results of the efficacy of vonoprazan‐based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. Methods: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords “vonoprazan,” “takecab”, “TAK‐438,” “potassium,” “competitive,” “potassium‐competitive,” “Helicobacter,” and “pylori.” Studies were included if they evaluated the eradication rate between the vonoprazan‐based and proton pump inhibitor (PPI)‐based triple therapies. Results: Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention‐to‐treat analysis was 87.9% and 72.8% in the vonoprazan‐based triple therapy and PPI‐based triple therapy respectively. The eradication rate of the vonoprazan‐based triple therapy was superior to that of the PPI‐based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15‐1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan‐based triple therapy [95% CI]=0.69 [0.23‐2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]=1.02 [0.78‐1.34]). Conclusions: The vonoprazan‐based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI‐based triple therapy. In addition, the vonoprazan‐based triple therapy showed comparable tolerability and incidence of adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“It was also assessed qualitatively by inspecting funnel plots of the logarithmic RR vs their standard errors.(35) The test for funnel plot asymmetry was not conducted when the included studies were fewer than 10.”
Method
Cited by
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Fallone, C. A., Moss, S. F., & Malfertheiner, P. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.011 · Cited by 286
Metadata
- Authors
- Jung, Y. S., Kim, E. H., & Park, C. H.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-05-12
- Volume
- 46
- Issue
- 2
- Pages
- 106-114
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2613485273
- Cited by
- 183
- References
- 3
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. https://app.cochat.ai/papers/10.1111/apt.14130
- The paper
- Jung, Y. S., Kim, E. H., & Park, C. H. (2017). Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.